Intrahepatic cholangiocarcinoma

Kimberly M. Brown, Abhishek D. Parmar, David A. Geller

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations


Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17% to 44%, with median survivals of 19 to 43months.

Original languageEnglish (US)
Pages (from-to)231-246
Number of pages16
JournalSurgical Oncology Clinics of North America
Issue number2
StatePublished - Apr 2014
Externally publishedYes


  • Bile duct neoplasms
  • Cholangiocarcinoma
  • Intrahepatic bile duct cancer
  • Intrahepatic cholangiocarcinoma
  • Peripheral cholangiocarcinoma

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Intrahepatic cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this